Mason Street Advisors LLC bought a new stake in Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) during the second quarter, Holdings Channel reports. The fund bought 12,363 shares of the biotechnology company’s stock, valued at approximately $134,000.
Several other large investors also recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Momenta Pharmaceuticals by 2.6% in the second quarter. FMR LLC now owns 10,632,879 shares of the biotechnology company’s stock valued at $114,835,000 after buying an additional 265,713 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Momenta Pharmaceuticals by 4.5% in the second quarter. BlackRock Fund Advisors now owns 4,922,956 shares of the biotechnology company’s stock valued at $53,168,000 after buying an additional 210,607 shares in the last quarter. Fiera Capital Corp bought a new stake in Momenta Pharmaceuticals during the second quarter valued at about $26,019,000. Palo Alto Investors LLC boosted its stake in Momenta Pharmaceuticals by 10.9% in the second quarter. Palo Alto Investors LLC now owns 1,629,076 shares of the biotechnology company’s stock valued at $17,594,000 after buying an additional 160,300 shares in the last quarter. Finally, Sector Gamma AS boosted its stake in Momenta Pharmaceuticals by 17.3% in the second quarter. Sector Gamma AS now owns 914,979 shares of the biotechnology company’s stock valued at $9,882,000 after buying an additional 134,666 shares in the last quarter. 81.09% of the stock is currently owned by institutional investors and hedge funds.
Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 12.05 on Monday. Momenta Pharmaceuticals Inc. has a 1-year low of $7.86 and a 1-year high of $18.85. The stock’s market cap is $826.59 million. The stock’s 50 day moving average is $11.91 and its 200-day moving average is $11.07.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.01. The firm had revenue of $26.40 million for the quarter, compared to the consensus estimate of $23.55 million. Momenta Pharmaceuticals had a negative return on equity of 28.76% and a negative net margin of 126.37%. The business’s revenue for the quarter was down 41.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) EPS. On average, analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.25) EPS for the current year.
MNTA has been the topic of several research analyst reports. Barclays PLC raised shares of Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $19.00 in a research report on Tuesday, October 11th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, October 4th. JPMorgan Chase & Co. decreased their target price on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, August 5th. Brean Capital set a $19.00 price target on shares of Momenta Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Cowen and Company restated a “hold” rating on shares of Momenta Pharmaceuticals in a report on Sunday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Momenta Pharmaceuticals currently has an average rating of “Buy” and an average price target of $15.78.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of Momenta Pharmaceuticals stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $12.02, for a total transaction of $70,677.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 6.10% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.